[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9703642A - Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana. - Google Patents

Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.

Info

Publication number
MX9703642A
MX9703642A MX9703642A MX9703642A MX9703642A MX 9703642 A MX9703642 A MX 9703642A MX 9703642 A MX9703642 A MX 9703642A MX 9703642 A MX9703642 A MX 9703642A MX 9703642 A MX9703642 A MX 9703642A
Authority
MX
Mexico
Prior art keywords
peptide analogues
multiple sclerosis
myelin basic
basic protein
treatment
Prior art date
Application number
MX9703642A
Other languages
English (en)
Inventor
Nicholas Ling
Paul J Conlon
Amitabh Gaur
Lawrence Steinman
Original Assignee
Neurocrine Biosciences Inc
Trustees Of The Leland Board O
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, Trustees Of The Leland Board O, Univ Leland Stanford Junior filed Critical Neurocrine Biosciences Inc
Publication of MX9703642A publication Critical patent/MX9703642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen análogos de péptido de proteína básica de mielina humana que contienen los residuos 87-99. El residuo 91 de los análogos de péptido es alterado del residuo de L-lisina encontrado en la proteína nativa a cualquier otro aminoácido. Se proveen composiciones farmacéuticas de los análogos de péptido. Además, los análogos de péptido se administran a pacientes con esclerosis multiple.
MX9703642A 1994-11-18 1997-05-16 Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana. MX9703642A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34207894A 1994-11-18 1994-11-18

Publications (1)

Publication Number Publication Date
MX9703642A true MX9703642A (es) 1998-11-29

Family

ID=23340234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703642A MX9703642A (es) 1994-11-18 1997-05-16 Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.

Country Status (9)

Country Link
US (4) US6369033B1 (es)
EP (2) EP0792286B1 (es)
JP (1) JPH10509714A (es)
AT (1) ATE213499T1 (es)
AU (1) AU721898B2 (es)
CA (1) CA2205532A1 (es)
DE (1) DE69525544T2 (es)
MX (1) MX9703642A (es)
WO (1) WO1996016085A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
ATE212358T1 (de) * 1992-04-09 2002-02-15 Autoimmune Inc Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0792286B1 (en) * 1994-11-18 2002-02-20 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basis protein for treatment of multiple scerosis
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
AU1874997A (en) * 1996-02-15 1997-09-02 Pangenetics B.V. Molecules for the induction of immunological tolerance
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6541608B1 (en) * 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
WO2002077025A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
CA2605321A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
NZ572644A (en) * 2006-05-05 2012-06-29 Opexa Therapeutics T-cell vaccine
SG172121A1 (en) 2008-12-19 2011-07-28 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
WO2012150495A1 (en) 2011-05-05 2012-11-08 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
CN103102393B (zh) * 2013-01-30 2015-01-07 北京大学 一种多肽及其在制备抑郁症治疗药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
BR9106114A (pt) * 1990-03-02 1993-03-09 Autoimmune Inc Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
ES2144418T3 (es) * 1991-05-31 2000-06-16 Connetics Corp Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
ATE212358T1 (de) * 1992-04-09 2002-02-15 Autoimmune Inc Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin
EP0720622A1 (en) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
EP0792286B1 (en) * 1994-11-18 2002-02-20 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basis protein for treatment of multiple scerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
AU721898B2 (en) 2000-07-20
DE69525544T2 (de) 2002-08-22
US6369033B1 (en) 2002-04-09
US20030114380A1 (en) 2003-06-19
US20040214775A1 (en) 2004-10-28
US6740638B2 (en) 2004-05-25
JPH10509714A (ja) 1998-09-22
US20020058627A1 (en) 2002-05-16
CA2205532A1 (en) 1996-05-30
US6489299B2 (en) 2002-12-03
DE69525544D1 (de) 2002-03-28
WO1996016085A1 (en) 1996-05-30
ATE213499T1 (de) 2002-03-15
AU4405796A (en) 1996-06-17
EP1172376A1 (en) 2002-01-16
EP0792286A1 (en) 1997-09-03
EP0792286B1 (en) 2002-02-20

Similar Documents

Publication Publication Date Title
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
ATE73459T1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
AU6819294A (en) Oral drug delivery compositions and methods
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
CA2303395A1 (en) Treatment of obesity
BR0213291A (pt) Composição e método para tratamento de diabetes
RU99103692A (ru) Аминокислотные композиции и их применение при иммунодепрессии
MY124560A (en) Amino acid compositions and use thereof in immunosuppression
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
DE3569541D1 (en) Pharmacologically active peptides
DE69430416D1 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
DE3462692D1 (en) Pharmacologically active peptides
EP0248231A3 (en) Pharmacologically active peptides
YU64192A (sh) Analozi insulina
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
AU2900989A (en) Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal